Alembic Pharmaceuticals (APLLTD) Fundamentals 2026 — P/E 23.7x, Revenue Analysis | SniperIQ
Alembic Pharmaceuticals (APLLTD) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹16,009 Crore, trading at ₹813.45 on the BSE. This SniperIQ fundamentals page covers Alembic Pharmaceuticals's valuation (P/E 23.7x, P/B 2.8x), profitability (net margin 9.2%), revenue (₹7,345 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Alembic Pharmaceuticals's market cap?
Alembic Pharmaceuticals (APLLTD) has a market capitalization of approximately ₹16,009 Crore, trading at ₹813.45 on the BSE. Market cap moves with the live share price.
What is Alembic Pharmaceuticals's P/E ratio?
Alembic Pharmaceuticals's trailing twelve-month P/E ratio is 23.7x, with a price-to-book (P/B) of 2.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Alembic Pharmaceuticals?
Alembic Pharmaceuticals runs a net profit margin of 9.2%, a gross margin of 51.8%, and an operating margin of 20.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Alembic Pharmaceuticals generate?
Alembic Pharmaceuticals reported revenue of ₹7,345 Crore for fiscal year 2026, with net income of ₹675 Crore and earnings per share (EPS) of 34.33. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Alembic Pharmaceuticals pay a dividend?
Alembic Pharmaceuticals offers a trailing dividend yield of about 1.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Alembic Pharmaceuticals financially healthy?
Alembic Pharmaceuticals carries a debt-to-equity ratio of 0.25x and a current ratio of 1.76x, with a market beta of 0.37. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Alembic Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Alembic Pharmaceuticals (APLLTD) the key facts are: market cap ₹16,009 Crore, P/E 23.7x, revenue ₹7,345 Crore, 52-week range 635.3-1029.7. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Alembic Pharmaceuticals's full fundamentals live
Get Alembic Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.